Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Meningococcal Group C Conjugate vaccine: MenC · 1 trial · 2 indications
Immunogenicity tests were performed at 19 months of age in Menactra Vaccine Group after Menactra® vaccination and performed at 13 months and 19 months of age in the Menjugate Vaccine Group after Menjugate® vaccination
Immunogenicity tests were performed at 19 months of age in Menactra Vaccine Group after Menactra® vaccination and performed at 13 months and 19 months of age in the Menjugate Vaccine Group after Menjugate® vaccination
| Arm | Type | Description |
|---|---|---|
| Menactra® Vaccine Group | EXPERIMENTAL | Meningococcal vaccine naive participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate vaccine (Menactra®) at 12 months of age and at 18 months of age concomitantly with routine vaccines administered as per provincial schedule |
| Menjugate® Vaccine Group | ACTIVE_COMPARATOR | Meningococcal vaccine naive participants will receive MenC vaccine (Menjugate) given concomitantly at 12 months of age with routine vaccines administered as per provincial schedule. |
| Name | Type | Description |
|---|---|---|
| Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra® | BIOLOGICAL | 0.5 mL, Intramuscular |
| Meningococcal Group C Conjugate vaccine: MenC | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria: * Aged 12 months (365 to 400 days) on the day of inclusion * Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg * Informed consent form has been signed and dated by the parent(s) or other legally authorized representative * Subject and parent/legal repr...
Meningococcal Group C Conjugate vaccine MenC is used for meningitis, specifically to prevent meningococcal infection caused by group C bacteria. It is an investigational vaccine being developed for this infectious disease indication.
Sanofi (ticker: SNY) is developing Meningococcal Group C Conjugate vaccine MenC. The vaccine is currently in Phase 3 clinical development for the prevention of meningitis and meningococcal infection.
Meningococcal Group C Conjugate vaccine MenC is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 3 trial has been completed.
Meningococcal Group C Conjugate vaccine MenC has one completed Phase 3 trial, NCT01359449, which studied two doses of Menactra or one dose of the monovalent vaccine with routine immunizations in 123 participants in Canada.
Meningococcal Group C Conjugate vaccine MenC is not the same as Menactra. The clinical trial NCT01359449 compared the monovalent MenC vaccine against Menactra, which is a different quadrivalent meningococcal vaccine used as an active control.